The study is a randomized, double-blinded, placebo controlled, crossover trial of allopurinol
for the treatment of children with newly diagnosed essential hypertension.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)